Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P210027/S019

QDOT MICRO BI-DIRECTIONAL NAVIGATION CATHETER; QDOT MICRO UNI-DIRECTIONAL NAVIGATION CATHETER

Biosense Webster, Inc. · Decision date Sep 15, 2026

MEDTECHLEDGER EXPLANATIONP210027/S019

What did the FDA decide?

Biosense Webster, Inc. received an OK30 decision dated 2026-09-15 for PMA supplement P210027/S019, a 30-Day Notice filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The supplement identifier links it to PMA P210027 for the QDOT MICRO bi-directional and uni-directional navigation catheters, product code OAE, described in the database as a percutaneous cardiac ablation catheter for treatment of atrial fibrillation. The notice's stated purpose is adding another supplier for critical components; the record does not name the components, the supplier, or the affected manufacturing site, and it gives no safety or performance data.

The decision does not approve the QDOT MICRO system as a new device; it covers a supplier change within the existing PMA. The reported purpose is a manufacturer's description of the change, not independent evidence of safety or clinical effectiveness, and the record states no new indication or clinical findings.

FDA approval order statement

an additional supplier for critical components
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Sep 15, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P210027/S019
Regulatory pathway
PMA supplement
Product code
OAE
Decision code
OK30
Decision date
Sep 15, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.

Product code
OAE
FDA device class
3

For the original device and its historical approval scope, see PMA P210027. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P210027 · Original PMA

    QDOT MICRO System

  2. P210027/S019 received

    Application receipt date recorded by FDA.

  3. P210027/S019 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P210027. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210027

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA approvalNov 23, 2022FDA
QDOT MICRO SystemP210027/S018
Biosense Webster, Inc.PMA supplementSep 10, 2026FDA

Explore the linked device profile

Other records with product code OAE

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biosense Webster, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
31 Technology Dr., Suite 200, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records